Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Being overweight or having obesity can affect your hormone levels, which can cause missed periods or, in other cases, heavy menstrual bleeding
Para continuar, ingresa atu cuenta trace-id: 3fea1353-b8c1-4d4c-8f55-74ee5c8604b7 Usamos cookies para mejorar tu experiencia en Mercado Libre
[29, 33] have demonstrated strong performance using transformer models and hybrid architectures for generalisation
Clinical evidence from studies like STEP 4 showed that discontinuing semaglutide led to significant weight regain in most participants, suggesting that long-term or indefinite use may be necessary for sustained results
event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
US$ 21.79
US$ 27.17
US$ 22.72
US$ 25.73
US$ 27.10
US$ 25.74
US$ 27.55
US$ 27.16
US$ 26.19
